MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2022 International Congress

    The results of DBS in patients with Parkinson’s disease for 10 years in Belarus

    A. Buniak, V. Alexeyevets, S. Likhachev (Minsk, Belarus)

    Objective: To study the efficiency and SE of DBS in PD patients in Republican Research and Clinical Center of Neurology and Neurosurgery in Belarus for…
  • MDS Virtual Congress 2021

    Early versus later levodopa and onset of motor fluctuations in PD: Observations from the Parkinson’s Outcomes Project

    S. Chiu, A. Ramirez-Zamora, B. Patel, S. Wu, H. Gao, O. Nguyen, I. Malaty (Gainesville, USA)

    Objective: To characterize patients with early versus later levodopa exposure, defining “early” as within 2 years of Parkinson’s disease (PD) diagnosis, and to determine whether…
  • MDS Virtual Congress 2021

    Risk factors for the onset of dyskinesia in patients with Parkinson’s disease exhibiting wearing-off phenomena: A 1-year observational study in Japan (J-FIRST)

    T. Mishima, SW. Chiu, H. Saiki, T. Yamaguchi, Y. Shimo, T. Maeda, H. Watanabe, K. Kashihara, M. Nomoto, N. Hattori, Y. Tsuboi (Fukuoka, Japan)

    Objective: To investigate the risk factors for the onset of dyskinesia in patients with Parkinson's disease (PD) exhibiting wearing-off phenomena. Background: Dyskinesia occurs during long-term…
  • MDS Virtual Congress 2021

    Determination of the motor status after the implementation Levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease using a Machine learning Algorithm

    E. Efthymiopoulou, A. Antonoglou, B. Loupo, A. Bougea (Athens, Greece)

    Objective: Aim of this study was to develop a random forest (RF)-based PD model to determine the postoperative motor outcome at 2 years follow-up after…
  • MDS Virtual Congress 2021

    Determination of 5-HT3 receptor levels with [3H]-GR 65630 binding in hemi-parkinsonian rats with L-DOPA induced dyskinesia

    C. Kwan, D. Bédard, I. Frouni, A. Hamadjida, P. Huot (Montreal, Canada)

    Objective: To determine the distribution of serotonin type 3 (5-HT3) receptors in brain areas implicated in L-3,4-dihydroxyphenylalanine (L-DOPA) induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat…
  • MDS Virtual Congress 2021

    Gut bacterial tyrosine decarboxylase as a predictive biomarker to identify Parkinson’s disease patients with motor fluctuations requiring frequent levodopa administration

    S. van Kessel, L. Verhagen Metman, G. Sanzo, P. Mcnamara, A. Keshavarzian, S. El Aidy (Groningen, Netherlands)

    Objective: To Investigate the clinical relevance of tyrosine decarboxylating (TDC)-bacteria in patients with Parkinson’s Disease (PD). Background: Recently, we have shown that TDC-gut bacteria that…
  • MDS Virtual Congress 2021

    Patterns of Cortical Thinning in Patients with Parkinson’s Disease

    H. Jergas, JC. Baldermann, JN. Petry-Schmelzer, H. Dafsari, V. Visser-Vanderwalle, T. Dembek, M. Barbe (Cologne, Germany)

    Objective: To investigate patterns of cortical thickness that are associated with disease severity and response to levodopa. Background: Cortex affection is a neuropathological correlate of…
  • MDS Virtual Congress 2021

    The GlyT1 inhibitor bitopertin reduces in the 6-OHDA-lesioned rat model of Parkinson’s disease

    I. Frouni, W. Kang, C. Kwan, D. Bedard, A. Hamadjida, P. Huot (Montreal, Canada)

    Objective: To determine the effect of glycine transporter 1 (GlyT1) inhibition with bitopertin on dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s disease (PD).…
  • MDS Virtual Congress 2021

    The modification of iron accumulation in nigrosome by levodopa treatment in early Parkinson’s disease

    MD. Wang, HC. Wang, HX. Wang, J. Wang, SJ. Lu, RL. Ge, JB. Chen (Binzhou, China)

    Objective: The study was to investigate the alteration of iron accumulation in nigrosome for the early treatment of dopamine loss in PD. Background: Iron accumulation…
  • MDS Virtual Congress 2021

    Effect of the GlyT1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset

    I. Frouni, SG. Nuara, D. Bédard, A. Hamadjida, JC. Gourdon, P. Huot (Montreal, Canada)

    Objective: To determine the effect of glycine transporter 1 (GlyT1) inhibition with ALX-5407 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism severity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An atypical and interesting feature of Parkinson´s disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • #23812 (not found)
  • Approaching Health Care Shaped by Generational Expectations (The AGE Study): Generational Perspective Related to Time
  • Application of the “5-2-1” Screening Criteria in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel: Interim Analysis from the DUOGLOBE Study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • DaTscan in clinical evaluation of Multiple System Atrophy
  • Decision-making process for opicapone’s bedtime regimen
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley